Project Grant R01HL183194
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $1.597 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion targeted for December 31, 2027. The grant supports basic research investigating mitochondrial quality control mechanisms in cardiac allograft vasculopathy (CAV), a significant complication limiting long-term...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $2.23 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2029. The award supports basic research investigating vascular proliferative resilience and endothelial cell biology in large blood vessels, specifically focusing on how the aorta maintains vascular...
- Federal Project Grant Award Summary Northwestern University received a $684,570 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through April 30, 2030. The award funds translational research and development of a bioengineered mitochondrial therapy platform designed to address endothelial injury and dysfunction in vascular surgery. The research deliverables include optimization of...
- Federal Grant Award Summary Northwestern University received a $150,104 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2025, with completion scheduled for September 14, 2027. The project deliverables center on developing tissue-engineered vascular grafts (TEVGs) resistant to calcification by utilizing matrix metalloprotease-degradable polyethylene glycol (MMP-PEG) hydrogels to coat...
- Federal Grant Award Summary Northwestern University received a $601,612 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award supports the development of an epicardial high-definition electrotherapy system for treatment of paroxysmal atrial fibrillation (AFib). The project will develop a fully implantable, organ-conformal device incorporating...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Northwestern University $249,000 on May 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a research training initiative through April 30, 2029. The funded project, "Mechanisms Linking the Frail Sarcomere to Noncompaction Cardiomyopathy," will deliver mechanistic research and analysis evaluating MYH7 (myosin heavy chain) gene variants associated with...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Northwestern University a Project Grant of $793,184 on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the AUTO2 Trial, a 2×2 factorial, patient-randomized controlled trial examining digitally-enabled home blood pressure monitoring strategies for patients with uncontrolled hypertension. The research will evaluate the comparative effectiveness of automated...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $1.59 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 25, 2026, with completion scheduled for May 31, 2028. The research addresses the disproportionate impact of pneumonia on elderly populations and the subsequent development of age-related pulmonary and systemic complications. The project...
- Federal Project Grant Summary Northwestern University's Sponsored Research Division received a $654,762 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026, through February 28, 2031. The research initiative focuses on elucidating the mechanisms by which regulatory T (Treg) cells limit persistent inflammation during recovery from viral pneumonia. The project investigates how Foxp3+...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $279,516 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026 through June 30, 2028. This exploratory/developmental grant (R21) funds a research initiative titled "Portable Echo for Aging Hearts: Assessing Cardiac Health in Older Adults with HIV" to evaluate the clinical utility,...
Grant Summary Northwestern University's Sponsored Research Division received a $914,694 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for June 30, 2031. The award funds the SimVAD Trial, a multi-center research initiative designed to evaluate the effectiveness and implementation of simulation-based mastery learning (SBML) training for patients with ventricular assist devices (VADs) and their caregivers across eight VAD implant centers. The project addresses a critical gap in standardized VAD self-care education, where current training practices vary widely across U.S. healthcare systems without requiring demonstrated competency before completion, resulting in variable skill acquisition and patient safety risks including driveline exit-site infections, re-hospitalizations, and preventable deaths. The primary products and services delivered under this grant include the development, evaluation, and implementation of the SimVAD training program, which employs competency-based simulation education to ensure patients and caregivers achieve standardized proficiency in daily VAD self-care management and recognition of critical symptoms. Building on preliminary pilot study results demonstrating superior skills and lower infection rates with SBML compared to traditional training approaches, Northwestern will conduct rigorous multi-center evaluation and dissemination activities to validate SimVAD's effectiveness across diverse VAD centers and establish protocols for broader adoption of this standardized, objective training methodology within the cardiovascular care community.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $914.7k | 7/10/26 |